Gradient Investments LLC reduced its position in shares of Eli Lilly and Company (NYSE:LLY – Get Rating) by 95.0% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 1,161 shares of the company’s stock after selling 22,018 shares during the quarter. Gradient Investments LLC’s holdings in Eli Lilly and were worth $376,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Cordant Inc. bought a new position in shares of Eli Lilly and in the first quarter valued at about $25,000. HWG Holdings LP bought a new position in shares of Eli Lilly and in the fourth quarter valued at about $28,000. Icapital Wealth LLC bought a new position in shares of Eli Lilly and in the first quarter valued at about $28,000. Selective Wealth Management Inc. bought a new position in shares of Eli Lilly and in the first quarter valued at about $33,000. Finally, Oliver Lagore Vanvalin Investment Group bought a new position in shares of Eli Lilly and in the first quarter valued at about $33,000. 82.45% of the stock is owned by institutional investors.
Analysts Set New Price Targets
Several equities analysts have recently weighed in on LLY shares. Morgan Stanley increased their price objective on shares of Eli Lilly and from $395.00 to $412.00 and gave the company an “overweight” rating in a research report on Wednesday, September 7th. UBS Group increased their price objective on shares of Eli Lilly and to $335.00 and gave the company an “outperform” rating in a research report on Wednesday, July 27th. Barclays upped their price target on shares of Eli Lilly and from $333.00 to $355.00 and gave the company an “overweight” rating in a research note on Thursday, July 7th. JPMorgan Chase & Co. upped their price target on shares of Eli Lilly and from $340.00 to $355.00 in a research note on Wednesday, June 1st. Finally, StockNews.com upgraded shares of Eli Lilly and from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, September 14th. Three research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $330.44.
Eli Lilly and Trading Down 1.2 %
Shares of Eli Lilly and stock opened at $305.09 on Tuesday. The company has a market capitalization of $289.89 billion, a price-to-earnings ratio of 48.66, a PEG ratio of 2.00 and a beta of 0.38. The company has a quick ratio of 0.85, a current ratio of 1.10 and a debt-to-equity ratio of 1.70. Eli Lilly and Company has a 12-month low of $220.20 and a 12-month high of $335.33. The firm’s 50-day moving average price is $316.13 and its two-hundred day moving average price is $303.88.
Eli Lilly and (NYSE:LLY – Get Rating) last posted its quarterly earnings results on Thursday, August 4th. The company reported $1.25 earnings per share for the quarter, missing analysts’ consensus estimates of $1.86 by ($0.61). Eli Lilly and had a net margin of 19.58% and a return on equity of 85.58%. The company had revenue of $6.49 billion during the quarter, compared to analyst estimates of $6.85 billion. During the same quarter in the previous year, the business posted $1.87 earnings per share. The company’s revenue for the quarter was down 3.7% on a year-over-year basis. On average, analysts forecast that Eli Lilly and Company will post 7.97 earnings per share for the current fiscal year.
Eli Lilly and Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Friday, September 9th. Stockholders of record on Monday, August 15th were paid a $0.98 dividend. The ex-dividend date was Friday, August 12th. This represents a $3.92 dividend on an annualized basis and a dividend yield of 1.28%. Eli Lilly and’s payout ratio is currently 62.52%.
Eli Lilly and Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.
- Get a free copy of the StockNews.com research report on Eli Lilly and (LLY)
- Oracle’s Short-Term Pain Could Be Your Long-Term Gain
- Lucid is Looking Like a Clear EV Winner
- Still Lovin’ It: Investors Keep Visiting McDonald’s
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.